

S1 Table. Pathoclinical profiles of the 12 patients whose tissue samples underwent RNA sequencing

ID	Sex	Age (yr)	Differentiation	T stage	N stage	M stage	CCT regimen	CCT cycle	RT technique	RT dose (Gy)	TRG
R1	Female	42	Moderately	3	2	0	CAPEOX	4	IMRT	50	3
R2	Male	63	Moderately	3	1	0	CAPEOX	4	IMRT	50	5
R3	Male	38	Moderately	3	1	0	CAPEOX	4	IMRT	50	4
R4	Male	60	Moderately	3	1	0	CAPEOX	4	IMRT	50	5
R5	Female	33	Moderately	4	0	0	CAPEOX	4	IMRT	50	3
R6	Female	63	Moderately	4	1	0	CAPEOX	4	IMRT	50	4
S1	Male	55	Well	3	2	0	CAPEOX	4	IMRT	50	1
S2	Male	75	Moderately	3	1	0	CAPEOX	4	IMRT	50	1
S3	Male	34	Moderately	3	1	0	CAPEOX	4	IMRT	50	1
S4	Male	55	Poorly	3	1	0	CAPEOX	4	IMRT	50	1
S5	Male	61	Well	3	1	0	CAPEOX	4	IMRT	50	1
S6	Male	37	Moderately	3	1	0	CAPEOX	4	IMRT	50	1

CCT, concurrent chemotherapy; RT, radiotherapy; TRG, tumor regression grade; CAPEOX, capecitabine plus oxaliplatin; IMRT, intensity-modulated radiotherapy.